Kezar Life Sciences, Inc. (KZR)
KZR Stock Price Chart
Explore Kezar Life Sciences, Inc. interactive price chart. Choose custom timeframes to analyze KZR price movements and trends.
KZR Company Profile
Discover essential business fundamentals and corporate details for Kezar Life Sciences, Inc. (KZR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Jun 2018
Employees
55.00
CEO
Christopher J. Kirk
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
KZR Financial Timeline
Browse a chronological timeline of Kezar Life Sciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$1.60.
Earnings released on 13 Aug 2025
EPS came in at -$1.87 surpassing the estimated -$2.15 by +13.02%.
Earnings released on 13 May 2025
EPS came in at -$2.27 surpassing the estimated -$2.56 by +11.33%.
Earnings released on 25 Mar 2025
EPS came in at -$2.77 falling short of the estimated -$2.71 by -2.21%.
Earnings released on 12 Nov 2024
EPS came in at -$2.78 surpassing the estimated -$3.03 by +8.25%.
Stock split effective on 30 Oct 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Aug 2024
EPS came in at -$2.80 surpassing the estimated -$3.20 by +12.50%.
Earnings released on 9 May 2024
EPS came in at -$3.00 surpassing the estimated -$3.40 by +11.76%.
Earnings released on 14 Mar 2024
EPS came in at -$3.50 surpassing the estimated -$3.90 by +10.26%, while revenue for the quarter reached -$5.43M .
Earnings released on 13 Nov 2023
EPS came in at -$3.20 surpassing the estimated -$3.60 by +11.11%, while revenue for the quarter reached $7.00M , beating expectations by +4.10K%.
Earnings released on 10 Aug 2023
EPS came in at -$3.40 falling short of the estimated -$3.30 by -3.03%.
Earnings released on 11 May 2023
EPS came in at -$3.10 falling short of the estimated -$2.80 by -10.71%.
Earnings released on 14 Mar 2023
EPS came in at -$2.50 falling short of the estimated -$2.40 by -4.17%.
Earnings released on 10 Nov 2022
EPS came in at -$2.50 surpassing the estimated -$2.60 by +3.85%.
Earnings released on 11 Aug 2022
EPS came in at -$2.50 surpassing the estimated -$2.70 by +7.41%.
Earnings released on 12 May 2022
EPS came in at -$2.60 surpassing the estimated -$2.90 by +10.34%.
Earnings released on 17 Mar 2022
EPS came in at -$2.50 surpassing the estimated -$2.90 by +13.79%.
Earnings released on 9 Nov 2021
EPS came in at -$2.80 falling short of the estimated -$2.60 by -7.69%.
Earnings released on 12 Aug 2021
EPS came in at -$2.50 surpassing the estimated -$2.60 by +3.85%.
Earnings released on 12 May 2021
EPS came in at -$2.50 falling short of the estimated -$2.40 by -4.17%.
Earnings released on 11 Mar 2021
EPS came in at -$2.20 surpassing the estimated -$2.50 by +12.00%.
Earnings released on 5 Nov 2020
EPS came in at -$2.30 falling short of the estimated -$2.10 by -9.52%.
KZR Stock Performance
Access detailed KZR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.